SCHEMBL4986388

SCHEMBL4986388

O=C(O)c1cccn(Cc2ccc3cc(F)ccc3c2)c1=O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
MEN1 O00255 1/20 0.54
HTT P42858 1/20 0.54
KMT2A Q03164 1/20 0.54
MAPT P10636 5/20 0.49
CNR1 P21554 3/20 0.49
CNR2 P34972 3/20 0.49
LMNA P02545 2/20 0.47
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
BRD4 O60885 2/20 0.46
BRD2 P25440 1/20 0.46
BRD3 Q15059 1/20 0.46
BRDT Q58F21 1/20 0.46
RAB9A P51151 1/20 0.45
HPGD P15428 1/20 0.45
ATM Q13315 1/20 0.45
PDPK1 O15530 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4433121 0.88 BRD4 (0.52) SMN1; SMN2L3MBTL1MEN1HTTKMT2A
SCHEMBL2621620 0.88 CNR1 (0.60) SMN1; SMN2L3MBTL1MEN1HTTKMT2A
SCHEMBL2621621 0.85 ALDH1A1 (0.59) SMN1; SMN2L3MBTL1MEN1HTTKMT2A
SCHEMBL4430754 0.85 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1MEN1HTTKMT2A
SCHEMBL4994990 0.83 MAPT (0.50) SMN1; SMN2L3MBTL1MEN1HTTKMT2A
SCHEMBL2621619 0.83 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1MEN1HTTKMT2A
SCHEMBL4431812 0.82 MAPT (0.54) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL19787908 0.80 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1MEN1HTTKMT2A
SCHEMBL2621639 0.79 SMN1; SMN2 (0.54) SMN1; SMN2L3MBTL1MEN1HTTKMT2A
SCHEMBL27793022 0.78 MAPT (0.44) SMN1; SMN2L3MBTL1MEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 SMN1; SMN2 2273/4885L3MBTL1 1671/4885MEN1 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.